ICTU is currently involved in three respiratory trials led by Investigators at Imperial College and the Royal Brompton and Harefield NHS Foundation Trust. The areas of research are: asthma, cystic fibrosis and interstitial lung disease.
AZALEA: A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 mg OD) as a Supplement to Standard Care for Adult Patients with Acute Exacerbations of Asthma
- The trial is looking at the use of the antibiotic azithromycin in treatment of patients following acute asthma attacks to show whether or not azithromycin in as an adjunct to standard care leads to quicker recovery from the exacerbation. The trial also examines the mechanism for azithromyci’s potential benefit i.e. - if it is having an anti-bacterial and/or anti-viral effect. Recruitment and follow up have completed for the study.
RECITAL: A randomised, double blind controlled trial comparing Rituximab against intravenous Cyclophosphamide in Connective Tissue Disease (CTD) associated Interstitial Lung Disease (ILD):
- A multi-centre randomised double-blind trial to compare the efficacy of rituximab and cyclophosphamide in patients with severe or progressive CTD-ILD. The trial is in the recruitment phase and aims to recruit 116 patients across multiple UK sites.
Repeated application of gene therapy in Cystic Fibrosis patients
- A randomised, placebo-controlled trial to assess whether repeated doses of gene therapy administered to the lungs of CF patients can lead to clinical